Role of vericiguat in management of patients with heart failure with reduced ejection fraction after worsening episode.

Worsening heart failure (HF) is a vulnerable period in which the patient has a markedly high risk of death or HF hospitalization (up to 10% and 30%, respectively, within the first weeks after episode). The prognosis of HF patients can be improved through a comprehensive approach that considers the d...

Descripción completa

Detalles Bibliográficos
Autores: Olivella A, Almenar-Bonet L, Moliner P, Coloma E, Martínez-Rubio A, Paz Bermejo M, Boixeda R, Cediel G, Méndez Fernández AB, Facila Rubio L
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Institución:Institut d'Investigació i Innovació Parc Taulí (I3PT)
Repositorio:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
OAI Identifier:oai:i3pt.fundanetsuite.com:p4368
Acceso en línea:https://i3pt.portalinvestigacion.com/publicaciones/4368
Access Level:acceso abierto
Palabra clave:Heart failure, SGLT2, Sacubitril-valsartan, Vericiguat, Worsening
id ES_68f993f2becf079ee4fc2663ccd666e9
oai_identifier_str oai:i3pt.fundanetsuite.com:p4368
network_acronym_str ES
network_name_str España
repository_id_str
spelling Role of vericiguat in management of patients with heart failure with reduced ejection fraction after worsening episode.Olivella AAlmenar-Bonet LMoliner PColoma EMartínez-Rubio APaz Bermejo MBoixeda RCediel GMéndez Fernández ABFacila Rubio LHeart failure, SGLT2, Sacubitril-valsartan, Vericiguat, WorseningWorsening heart failure (HF) is a vulnerable period in which the patient has a markedly high risk of death or HF hospitalization (up to 10% and 30%, respectively, within the first weeks after episode). The prognosis of HF patients can be improved through a comprehensive approach that considers the different neurohormonal systems, with the early introduction and optimization of the quadruple therapy with sacubitril-valsartan, beta-blockers, mineralocorticoid receptor antagonists, and inhibitors. Despite that, there is a residual risk that is not targeted with these therapies. Currently, it is recognized that the cyclic guanosine monophosphate deficiency has a negative direct impact on the pathogenesis of HF, and vericiguat, an oral stimulator of soluble guanylate cyclase, can restore this pathway. The effect of vericiguat has been explored in the VICTORIA study, the largest chronic HF clinical trial that has mainly focused on patients with recent worsening HF, evidencing a significant 10% risk reduction of the primary composite endpoint of cardiovascular death or HF hospitalization (number needed to treat 24), after adding vericiguat to standard therapy. This benefit was independent of background HF therapy. Therefore, optimization of treatment should be performed as earlier as possible, particularly within vulnerable periods, considering also the use of vericiguat.OXFORD UNIV PRESS2024info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://i3pt.portalinvestigacion.com/publicaciones/4368ESC Heart FailureISSN: 20555822reponame:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulíinstname:Institut d'Investigació i Innovació Parc Taulí (I3PT)Inglésinfo:eu-repo/semantics/openAccessoai:i3pt.fundanetsuite.com:p43682026-06-21T15:30:37Z
dc.title.none.fl_str_mv Role of vericiguat in management of patients with heart failure with reduced ejection fraction after worsening episode.
title Role of vericiguat in management of patients with heart failure with reduced ejection fraction after worsening episode.
spellingShingle Role of vericiguat in management of patients with heart failure with reduced ejection fraction after worsening episode.
Olivella A
Heart failure, SGLT2, Sacubitril-valsartan, Vericiguat, Worsening
title_short Role of vericiguat in management of patients with heart failure with reduced ejection fraction after worsening episode.
title_full Role of vericiguat in management of patients with heart failure with reduced ejection fraction after worsening episode.
title_fullStr Role of vericiguat in management of patients with heart failure with reduced ejection fraction after worsening episode.
title_full_unstemmed Role of vericiguat in management of patients with heart failure with reduced ejection fraction after worsening episode.
title_sort Role of vericiguat in management of patients with heart failure with reduced ejection fraction after worsening episode.
dc.creator.none.fl_str_mv Olivella A
Almenar-Bonet L
Moliner P
Coloma E
Martínez-Rubio A
Paz Bermejo M
Boixeda R
Cediel G
Méndez Fernández AB
Facila Rubio L
author Olivella A
author_facet Olivella A
Almenar-Bonet L
Moliner P
Coloma E
Martínez-Rubio A
Paz Bermejo M
Boixeda R
Cediel G
Méndez Fernández AB
Facila Rubio L
author_role author
author2 Almenar-Bonet L
Moliner P
Coloma E
Martínez-Rubio A
Paz Bermejo M
Boixeda R
Cediel G
Méndez Fernández AB
Facila Rubio L
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Heart failure, SGLT2, Sacubitril-valsartan, Vericiguat, Worsening
topic Heart failure, SGLT2, Sacubitril-valsartan, Vericiguat, Worsening
description Worsening heart failure (HF) is a vulnerable period in which the patient has a markedly high risk of death or HF hospitalization (up to 10% and 30%, respectively, within the first weeks after episode). The prognosis of HF patients can be improved through a comprehensive approach that considers the different neurohormonal systems, with the early introduction and optimization of the quadruple therapy with sacubitril-valsartan, beta-blockers, mineralocorticoid receptor antagonists, and inhibitors. Despite that, there is a residual risk that is not targeted with these therapies. Currently, it is recognized that the cyclic guanosine monophosphate deficiency has a negative direct impact on the pathogenesis of HF, and vericiguat, an oral stimulator of soluble guanylate cyclase, can restore this pathway. The effect of vericiguat has been explored in the VICTORIA study, the largest chronic HF clinical trial that has mainly focused on patients with recent worsening HF, evidencing a significant 10% risk reduction of the primary composite endpoint of cardiovascular death or HF hospitalization (number needed to treat 24), after adding vericiguat to standard therapy. This benefit was independent of background HF therapy. Therefore, optimization of treatment should be performed as earlier as possible, particularly within vulnerable periods, considering also the use of vericiguat.
publishDate 2024
dc.date.none.fl_str_mv 2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://i3pt.portalinvestigacion.com/publicaciones/4368
url https://i3pt.portalinvestigacion.com/publicaciones/4368
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv OXFORD UNIV PRESS
publisher.none.fl_str_mv OXFORD UNIV PRESS
dc.source.none.fl_str_mv ESC Heart Failure
ISSN: 20555822
reponame:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
instname:Institut d'Investigació i Innovació Parc Taulí (I3PT)
instname_str Institut d'Investigació i Innovació Parc Taulí (I3PT)
reponame_str r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
collection r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869409998288715776
score 15.81155

Similares en LA Referencia